These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 23650874)

  • 41. [Immunotherapy for metastatic prostate cancer: do we really need this?].
    Heidenreich A
    Urologe A; 2012 Jan; 51(1):32-8. PubMed ID: 22258374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New treatments for metastic prostate cancer.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current and emerging treatments in the management of castration-resistant prostate cancer.
    Shapiro D; Tareen B
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequencing Treatment for Castration-Resistant Prostate Cancer.
    Handy CE; Antonarakis ES
    Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New treatment options for castrate-resistant prostate cancer: a urology perspective.
    Gomella LG; Gelpi F; Kelly WK
    Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.
    Saad F; Miller K
    Urology; 2015 May; 85(5):976-986. PubMed ID: 25709051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
    Davis K; Wood S; Dill E; Fesko Y; Bitting RL; Harrison MR; Armstrong AJ; Moul JW; George DJ
    Clin J Oncol Nurs; 2015 Jun; 19(3):297-303. PubMed ID: 26000580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Strategy in advanced castration-resistant prostate cancer].
    Gross-Goupil M; Roca S; Pasticier G; Ravaud A
    Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current status of immunological approaches for the treatment of prostate cancer.
    Drake CG; Antonarakis ES
    Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
    Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
    Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6 Suppl 12):1-15. PubMed ID: 22361744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy in prostate cancer: review of the current evidence.
    Fernández-García EM; Vera-Badillo FE; Perez-Valderrama B; Matos-Pita AS; Duran I
    Clin Transl Oncol; 2015 May; 17(5):339-57. PubMed ID: 25480118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.